(Q44718887)

English

Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China

scientific article published on September 25, 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

chronic phase chronic myelogenous leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

14

object named as

Fan-yi Meng

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20872002

20 July 2024

author name string

Qi-fa Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Xiao-jun Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Yin-kui Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Jing Sun

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Yu Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Zhi-ping Fan

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Dan Xu

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Qian-li Jiang

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Yong-qiang Wei

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Fen Huang

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Ru Feng

11

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Xiao-li Liu

12

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Bing Xu

13

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20872002

20 July 2024

publication date

25 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

full work available at URL

http://link.springer.com/content/pdf/10.1007/s00277-010-1081-3.pdf

Portable Document Format

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

http://link.springer.com/article/10.1007/s00277-010-1081-3/fulltext.html

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

http://link.springer.com/content/pdf/10.1007/s00277-010-1081-3

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

90

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

331-341

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Current and emerging treatment options in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host dis

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-010-1081-3

21 January 2018

Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities

1

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings

9

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group

13

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Karnofsky performance status revisited: reliability, validity, and guidelines

19

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Graft-versus-host disease

23

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation

25

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study

30

1 reference

10.1007/S00277-010-1081-3

https://api.crossref.org/works/10.1007/S00277-010-1081-3

20 July 2024

Identifiers

10.1007/S00277-010-1081-3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44718887&oldid=2209050867"